143 related articles for article (PubMed ID: 22641675)
1. β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
Uto Y; Yamamoto S; Mukai H; Ishiyama N; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Hori H
Anticancer Res; 2012 Jun; 32(6):2359-64. PubMed ID: 22641675
[TBL] [Abstract][Full Text] [Related]
2. Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.
Uto Y; Yamamoto S; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Nakata E; Hori H
Anticancer Res; 2011 Jul; 31(7):2489-92. PubMed ID: 21873164
[TBL] [Abstract][Full Text] [Related]
3. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Anticancer Res; 2002; 22(6C):4297-300. PubMed ID: 12553073
[TBL] [Abstract][Full Text] [Related]
4. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.
Yamamoto N; Kumashiro R
J Immunol; 1993 Sep; 151(5):2794-802. PubMed ID: 8360493
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N; Suyama H; Yamamoto N; Ushijima N
Int J Cancer; 2008 Jan; 122(2):461-7. PubMed ID: 17935130
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N; Suyama H; Nakazato H; Yamamoto N; Koga Y
Cancer Immunol Immunother; 2008 Jul; 57(7):1007-16. PubMed ID: 18058096
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
8. Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.
Kuchiike D; Uto Y; Mukai H; Ishiyama N; Abe C; Tanaka D; Kawai T; Kubo K; Mette M; Inui T; Endo Y; Hori H
Anticancer Res; 2013 Jul; 33(7):2881-5. PubMed ID: 23780974
[TBL] [Abstract][Full Text] [Related]
9. Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein.
Nagasawa H; Sasaki H; Uto Y; Kubo S; Hori H
Anticancer Res; 2004; 24(5C):3361-6. PubMed ID: 15515432
[TBL] [Abstract][Full Text] [Related]
10. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Yamamoto N; Naraparaju VR; Asbell SO
Cancer Res; 1996 Jun; 56(12):2827-31. PubMed ID: 8665521
[TBL] [Abstract][Full Text] [Related]
11. Role of vitamin D3-binding protein in activation of mouse macrophages.
Yamamoto N; Naraparaju VR
J Immunol; 1996 Aug; 157(4):1744-9. PubMed ID: 8759764
[TBL] [Abstract][Full Text] [Related]
12. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.
Nagasawa H; Uto Y; Sasaki H; Okamura N; Murakami A; Kubo S; Kirk KL; Hori H
Anticancer Res; 2005; 25(6A):3689-95. PubMed ID: 16302727
[TBL] [Abstract][Full Text] [Related]
13. Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.
Mohamad SB; Nagasawa H; Sasaki H; Uto Y; Nakagawa Y; Kawashima K; Hori H
Anticancer Res; 2003; 23(6a):4451-7. PubMed ID: 14666733
[TBL] [Abstract][Full Text] [Related]
14. Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production.
Uto Y; Kawai T; Sasaki T; Hamada K; Yamada H; Kuchiike D; Kubo K; Inui T; Mette M; Tokunaga K; Hayakawa A; Go A; Oosaki T
Anticancer Res; 2015 Aug; 35(8):4487-92. PubMed ID: 26168491
[TBL] [Abstract][Full Text] [Related]
15. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.
Yamamoto N; Naraparaju VR; Srinivasula SM
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1373-8. PubMed ID: 8573395
[TBL] [Abstract][Full Text] [Related]
16. A novel assay system for macrophage-activating factor activity using a human U937 cell line.
Ishikawa M; Inoue T; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2014 Aug; 34(8):4577-81. PubMed ID: 25075102
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of degalactosylated gc-globulin on orthotopic grafted lung cancer in mice.
Hirota K; Nakagawa Y; Takeuchi R; Uto Y; Hori H; Onizuka S; Terada H
Anticancer Res; 2013 Jul; 33(7):2911-5. PubMed ID: 23780979
[TBL] [Abstract][Full Text] [Related]
18. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages.
Yamamoto N; Homma S; Millman I
J Immunol; 1991 Jul; 147(1):273-80. PubMed ID: 2051023
[TBL] [Abstract][Full Text] [Related]
19. A designed glycoprotein analogue of Gc-MAF exhibits native-like phagocytic activity.
Bogani F; McConnell E; Joshi L; Chang Y; Ghirlanda G
J Am Chem Soc; 2006 Jun; 128(22):7142-3. PubMed ID: 16734450
[TBL] [Abstract][Full Text] [Related]
20. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats.
Yamamoto N; Lindsay DD; Naraparaju VR; Ireland RA; Popoff SN
J Immunol; 1994 May; 152(10):5100-7. PubMed ID: 8176226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]